XTX Topco Ltd Cuts Stock Position in Ventyx Biosciences, Inc. (NASDAQ:VTYX)

XTX Topco Ltd lessened its stake in Ventyx Biosciences, Inc. (NASDAQ:VTYXFree Report) by 50.8% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 48,951 shares of the company’s stock after selling 50,472 shares during the period. XTX Topco Ltd’s holdings in Ventyx Biosciences were worth $56,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its stake in Ventyx Biosciences by 376.4% in the fourth quarter. Bank of America Corp DE now owns 4,273,442 shares of the company’s stock valued at $9,359,000 after purchasing an additional 3,376,446 shares during the last quarter. Vestal Point Capital LP grew its stake in Ventyx Biosciences by 15.9% in the fourth quarter. Vestal Point Capital LP now owns 2,000,000 shares of the company’s stock valued at $4,380,000 after purchasing an additional 275,000 shares during the last quarter. Point72 Asset Management L.P. purchased a new position in Ventyx Biosciences in the fourth quarter valued at about $3,903,000. Geode Capital Management LLC grew its stake in shares of Ventyx Biosciences by 1.5% during the fourth quarter. Geode Capital Management LLC now owns 1,413,039 shares of the company’s stock worth $3,095,000 after acquiring an additional 21,337 shares during the last quarter. Finally, Millennium Management LLC grew its stake in shares of Ventyx Biosciences by 369.7% during the fourth quarter. Millennium Management LLC now owns 1,281,629 shares of the company’s stock worth $2,807,000 after acquiring an additional 1,008,760 shares during the last quarter. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Stock Performance

Shares of VTYX stock opened at $2.83 on Friday. Ventyx Biosciences, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $3.39. The firm has a market capitalization of $201.81 million, a price-to-earnings ratio of -1.68 and a beta of 0.97. The stock’s 50-day simple moving average is $2.61 and its 200-day simple moving average is $1.84.

Ventyx Biosciences (NASDAQ:VTYXGet Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.07. As a group, equities analysts forecast that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Ventyx Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th.

View Our Latest Analysis on VTYX

About Ventyx Biosciences

(Free Report)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.

Recommended Stories

Want to see what other hedge funds are holding VTYX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ventyx Biosciences, Inc. (NASDAQ:VTYXFree Report).

Institutional Ownership by Quarter for Ventyx Biosciences (NASDAQ:VTYX)

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.